Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | Human |
Product Type | Organoid |
Tissue | Hepatocellular carcinoma, Total necrotic lesion |
Disease | Hepatocellular carcinoma |
Applications
Oncology
The oncology drug efficacy evaluation platform is based on patient-derived organoids(PDOs).
This platform allows for the assessment of the efficacy of oncology agents and immunotherapeutics by utilizing a co-culture system with immune cells from the tumor microenvironment.
Immuno-Oncology
This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.
Tumormicroenvironment
CAFs promote cancer invasion and metastasis, potentially inducing resistance to anticancer drugs. Considering these functions of CAFs is crucial for accurately assessing the efficacy of anticancer drugs and developing strategies to address these challenges.
Cancer Vaccine
Lead the future of treatment with our innovative cancer vaccine and mRNA therapy platform.
Discover advanced solutions that provide better health and hope through our cutting-edge technology and scientific approach
The hepatocellular carcinoma (HCC) organoids we create exhibit the same marker expression patterns, such as AFP positivity, CK19 negativity, and HepPar1 positivity, as the patient tissues they are derived from.
These organoids can be utilized for personalized drug testing, disease modeling, and biomarker discovery, ensuring that therapeutic strategies are tailored to the specific characteristics of each patient’s tumor.
We provide a valuable platform for developing and testing targeted therapies and studying tumor microenvironment interactions.
Hepatocarcinoma cancer organoid
H&E | AFP | CK19 | EpCAM | HepPar 1 | |
|---|---|---|---|---|---|
Cancer tissue |  |  |  |  |  |
Cancer organoid |  |  |  |  |  |
Our histological analysis demonstrated that the organoids faithfully replicated the expression patterns of critical markers AFP, CK19, EpCAM, and HepPar1 found in the original tissues.
This alignment proves the efficacy of our organoids for precise disease modeling and medical research, paving the way for targeted therapeutic applications and biomarker discovery.
Performing WES analysis on 7 hepatocarcinoma (hHCC) samples, the top 28 gene mutations were noticeably present across the samples, indicating a high level of mutation. According to these results, conducting experiments using the various types of hepatocarcinoma samples we possess will likely yield results similar to those observed in actual human cases.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
